SCHEMBL503366

SCHEMBL503366

CC1(N)CCCCN1Oc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN1 Q05586 2/20 0.39
KCNH2 Q12809 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
CYP2B6 P20813 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
PRCP P42785 1/20 0.39
SLC6A3 Q01959 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
OPRM1 P35372 3/20 0.38
OPRD1 P41143 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CYP2D6 P10635 1/20 0.38
DRD4 P21917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558226 0.83 GRIN1 (0.37) GRIN2DGRIN3BGRIN1KCNH2GRIN2A
SCHEMBL8120914 0.70 GRIN2D (0.42) GRIN2DGRIN3BGRIN1KCNH2GRIN2A
SCHEMBL10670349 0.67 SIGMAR1 (0.59) GRIN2DGRIN3BGRIN1KCNH2GRIN2A
SCHEMBL8552014 0.66 GRIN2D (0.48) GRIN2DGRIN3BGRIN1KCNH2GRIN2A
SCHEMBL6501299 0.66 CA4 (0.34) GRIN2DGRIN3BGRIN1KCNH2GRIN2A
SCHEMBL1827943 0.65 LTA4H (0.40) KCNH2CYP2D6
SCHEMBL1456783 0.64 CYP2D6 (0.41) KCNH2CYP2B6SIGMAR1CYP2D6
SCHEMBL28643916 0.64 CYP2D6 (0.41) KCNH2CYP2B6SIGMAR1CYP2D6
SCHEMBL74752 0.64 CYP2D6 (0.41) KCNH2CYP2B6SIGMAR1CYP2D6
SCHEMBL27593274 0.63 GRIN1 (0.46) GRIN2DGRIN3BGRIN1KCNH2GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1576134-B1 METHOD FOR DISCOVERING NEUROGENIC AGENTS KELLEHER-ANDERSSON JUDITH (US) 2013-03-06 EP claimed
US-8846914-B2 Compositions to effect neuronal growth NEURALSTEM, INC. (US) 2014-09-30 US disclosed
US-20140147424-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH NEURALSTEM, INC. (US) 2014-05-29 US disclosed
US-8674098-B2 Compositions to effect neuronal growth NEURALSTEM, INC. (US) 2014-03-18 US disclosed
US-20130195816-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH NEURALSTEM, INC. (US) 2013-08-01 US disclosed
US-8362262-B2 Compositions to effect neuronal growth NEURALSTEM, INC. (US) 2013-01-29 US disclosed
US-20120027733-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH NEURALSTEM, INC. (US) 2012-02-02 US disclosed
US-8058434-B2 Compositions to effect neuronal growth NEURALSTEM, INC. (US) 2011-11-15 US disclosed
US-8030492-B2 Compositions to effect neuronal growth NEURALSTEM, INC. (US) 2011-10-04 US disclosed
US-20110135612-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH NEURALSTEM, INC. 2011-06-09 US disclosed
US-20110052552-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH NEURALSTEM, INC. 2011-03-03 US disclosed
US-7858628-B2 inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans NEURALSTEM, INC. (US) 2010-12-28 US disclosed
US-20100034784-A1 inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans NEURALSTEM, INC. (US) 2010-02-11 US disclosed
US-7560553-B1 1-(Pyrid-4-yl-methyl-),4-((6-piperazino)pyrid-5-yl)-piperazine; proliferation/differentiation of human hippocampal multipotent stem/progenitor cells and neuronal progenitors; drug screening; learning enhancement; cognition activators; Alzheimer's disease; antidepressants; brain trauma; neuroprotectants NEURALSTEM, INC. (US) 2009-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100034784-A1 inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans DCX, MKI67, INA GRIN2D 88/4885GRIN3B 35/4885GRIN1 32/4885
US-20140147424-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH GAP43, NGF, NEFM GRIN2D 83/4885GRIN3B 33/4885GRIN1 39/4885
US-20110052552-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH GAP43, NGF, NEFM GRIN2D 67/4885GRIN3B 35/4885GRIN1 32/4885
US-20110135612-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH GAP43, NGF, NEFM GRIN2D 83/4885GRIN3B 33/4885GRIN1 39/4885
US-20130195816-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH GAP43, NGF, NEFM GRIN2D 83/4885GRIN3B 33/4885GRIN1 39/4885
US-20120027733-A1 COMPOSITIONS TO EFFECT NEURONAL GROWTH GAP43, NGF, NEFM GRIN2D 83/4885GRIN3B 33/4885GRIN1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.